Medicare has proposed reducing payments to hospitals for certain drugs and imaging services as part of a new step toward site‑neutral reimbursement, according to STAT News. The change would bring payment levels for identical clinical services into closer alignment, no matter if they’re delivered in a hospital outpatient department or a physician’s office.
The proposal marks another turn in the long campaign for site‑neutral payment reform. Under that framework, the same service receives the same Medicare rate, regardless of location. If finalized, the shift would narrow margins on outpatient‑administered drugs and diagnostics, most notably in hospital‑owned clinics. The immediate result: more pressure on hospital finances. Over time, possible movement of patients toward lower‑cost ambulatory sites. For payers and PBMs, the adjustments could mean lower total spend per service, paired with a more complicated network strategy.
From an analytical view, this move suggests CMS is testing how far site‑neutral policy can go within Medicare’s structure. Should the payment reduction hold, commercial insurers may follow with similar adjustments, further compressing the hospital outpatient premium. Observers will be watching to see whether hospitals pursue legal or legislative challenges; past site‑neutral reductions have ended up in court. And Congress could step in. The outlook heading into 2026 remains straightforward enough: price differentials based on care setting are still under pressure, with drug administration and imaging newly drawn into focus.
